Pharmaceutical giant Pfizer is in contact with Israeli companies Gamida Cell and TEVA, with intent of commercializing Gamida Cell’s StemEX, a treatments for lymphoma and leukemia (which is partially owned by TEVA). Israeli economics magazine Calcalist reports that if the deal goes through, Gamida cell will receive tens of millions of dollars in advance plus grants for milestones reached. Gamida Cell specializes in developing stem cell therapy projects.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments